We are currently investigating possible Dupixent cancer lawsuits for patients who were diagnosed with a type of cutaneous T-cell lymphoma (CTCL), such as mycosis fungoides (MF) or Sézary syndrome, after they started using Dupixent.
The Dupixent cancer lawsuits would be filed against the manufacturers of Dupixent, Sanofi and Regeneron, based on the allegation that those two pharmaceutical companies failed to warn patients and doctors about the possible increased risk of cutaneous T-cell lymphoma (CTCL).
In more detail, there is a growing body of medical evidence showing an association between Dupixent and cutaneous T-cell lymphoma (CTCL), which has given rise to Dupixent cancer lawsuits being filed on behalf of patients diagnosed with this CTCL cancer on their skin.
To start, this April 2024 medical article, “Dupilumab treatment for atopic dermatitis linked to cutaneous T-cell lymphoma development“, published online by Healio, presented some findings from a recent study that showed patients using Dupixent (dupilumab) for treatment of their atopic dermatitis had an increased risk for cutaneous T-cell lymphoma (CTCL).
The complete findings from that Dupixent – CTCL study were reported in this medical journal article, “Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study“, published by the Journal of the American Academy of Dermatology in their August 2024 print edition.
The following information about cutaneous T-cell lymphoma (CTCL) comes from the Cutaneous Lymphoma Foundation website.
- Cutaneous T-cell lymphoma (CTCL) is the most common type of cutaneous lymphoma, and typically presents with red, scaly patches or plaques on the skin. Itching is common, with more than 80% of people with CTCL reporting they have itch. CTCL often mimics eczema, psoriasis, or other chronic dermatitis, and because of this it’s common that the diagnosis of CTCL is delayed, sometimes by years or decades….
- Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL). Although the terms MF and CTCL are often used interchangeably, this can be a source of confusion. All cases of MF are CTCL, but not all CTCL cases are MF.
- Sézary syndrome is a leukemic form of CTCL, and distinguished from mycosis fungoides by the presence of cancerous lymphocytes in the blood.
Feel free to submit a Drug Injury Case Evaluation Form online or call 910-256-2971 if we can assist you with a possible Dupixent cancer lawsuit.
[Read the article in full at source]Dupixent
Free Case Evaluation
Strictly Confidential, No Obligation